EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

Who Took Part

The abstract describes 311 patients taking part.

By PubMed's age tags, the people studied were older adults.

A post hoc analysis compared results of patients aged ≥65 versus <65 years from DUAL II, III, and V.

These were 26-week, phase 3, randomized, twoarm parallel, treat-to-target trials in patients already taking injectable glucose-lowering agents.

How the Study Was Run

The researchers set it up as a randomized and parallel-group study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the patients stayed in one arm throughout.

The researchers evaluated 311 patients aged <65 and 87 patients aged ≥65 years from DUAL II, 326 patients <65 years and 112 patients ≥65 years from DUAL III, and 412 patients <65 years and 145 patients ≥65 years from DUAL V.

Patients were randomized to IDegLira or insulin degludec (DUAL II), IDegLira or unchanged glucagon-like peptide 1-receptor agonist (GLP-1RA) (DUAL III), or IDegLira or IGlar U100 (DUAL V).

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Drug Combinations, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Glargine and Insulin, Long-Acting.

What This Means in Plain Language

The paper is a randomized and parallel-group study of Liraglutide in 311 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Liraglutide compound page.